Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.NS)
- Previous Close
333.35 - Open
332.00 - Bid --
- Ask --
- Day's Range
330.35 - 346.00 - 52 Week Range
273.60 - 514.85 - Volume
80,320 - Avg. Volume
45,865 - Market Cap (intraday)
9.083B - Beta (5Y Monthly) 0.99
- PE Ratio (TTM)
36.94 - EPS (TTM)
9.30 - Earnings Date May 21, 2024 - May 25, 2024
- Forward Dividend & Yield 5.00 (1.50%)
- Ex-Dividend Date Aug 21, 2023
- 1y Target Est
--
Jagsonpal Pharmaceuticals Limited engages in the manufacture and trading of pharmaceutical products and active pharmaceutical ingredients in the areas in the areas of women health, pain and analgesics, and general medicine in India and internationally. It offers pharmaceutical formulations and over the counter drugs in the areas of gynaecology, orthopaedics, and allergy management. It offers drugs in the form of tablets, softgels, injections, capsules, and syrups. The company was incorporated in 1978 and is headquartered in New Delhi, India.
www.jagsonpal.com940
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: JAGSNPHARM.NS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: JAGSNPHARM.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: JAGSNPHARM.NS
Valuation Measures
Market Cap
8.79B
Enterprise Value
7.76B
Trailing P/E
35.88
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.99
Price/Book (mrq)
5.20
Enterprise Value/Revenue
3.52
Enterprise Value/EBITDA
22.14
Financial Highlights
Profitability and Income Statement
Profit Margin
11.11%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
2.21B
Net Income Avi to Common (ttm)
245.17M
Diluted EPS (ttm)
9.30
Balance Sheet and Cash Flow
Total Cash (mrq)
1.12B
Total Debt/Equity (mrq)
5.50%
Levered Free Cash Flow (ttm)
--
Company Insights: JAGSNPHARM.NS
JAGSNPHARM.NS does not have Company Insights